Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus radiotherapy for previously treated or relapsed metastatic biliary tract cancer
ChiCTR2400081259Phase 2Recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Feb 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in biliary cancer, sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoints: objective response rate, progression-free survival and 1 more. Started Feb 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2400081259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081259.